2 thoughts on “Brexit and pharmaceuticals – separating fear from reality”

  1. Posted 06/06/2019 at 16:57 | Permalink

    “If the UK were to continue to recognise EEA MAs, whilst also making improvements to our national system and working with regulators in other jurisdictions like China, Japan and Australia, to speed up authorisations, as suggested by Sir Michael Rawlins in his evidence to the HOC Health and Social Care Committee, this could mean the UK will benefit from more medicines being available more quickly”

    So the UK would rely on other countries to make the decisions over what drugs are licensed, without any input into the regulatory system?
    That is what I call TAKING BACK CONTROL. Oh no… Wait…..

  2. Posted 12/06/2019 at 07:38 | Permalink

    Marc, I’m not correlating co-op with other states meaning a loss of control. In fact the central tenet of the document is how, having control, we could unilaterally completely eliminate tariffs on this sector, given it has apparently limited impact on industry protection.

    By the way, writing in capitals doesn’t strengthen your argument.

Leave a Reply

Your e-mail address will not be published.